Organ-on-Chip technology involves the creation of microscale devices that mimic the structure, function, and physiological responses of human organs. These chips can be used to test the efficacy and safety of drugs before they are tested in humans or animals.
Traditional drug testing methods using animal models or in vitro cell cultures often fail to accurately predict human responses due to differences in biology and physiology. Organ-on-Chip technology provides a more accurate model for predicting drug efficacy and toxicity, reducing the need for animal testing and improving the success rate of clinical trials.
Miniaturized organs on a chip contain living cells from various tissues arranged in a way that mimics their natural environment. Fluidic channels within the device allow for the flow of nutrients, oxygen, and other substances necessary for cell survival and function. These chips can be used to study drug interactions with specific organ systems, such as the liver or heart.
The fabrication process involves microfabrication techniques such as soft lithography or photolithography to create channels and chambers on a substrate. Living cells are then cultured within these structures using bioreactor systems that mimic physiological conditions.
Cells from various tissues (e.g., liver, heart) are isolated and differentiated in vitro before being seeded onto the microfluidic chips. The device is then integrated with fluidic channels to provide a continuous flow of nutrients and signaling molecules necessary for cell survival and function.
Curated names only — none are invented. Use the link to find more.
Cost drivers only — no verified dollar figures are shown. Check live sources for prices.
Illustrative — search real, dated examples rather than trusting a generated story.
Live searches — we don't list papers we can't verify.
Live patent searches — filings are never listed from memory.
Verify against primary sources only.
Source: curated technology intelligence stream with tracked references.